Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avibactam is a non-β-lactam β-lactamase inhibitor used in combination with ceftazidime for the treatment of complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), and hospital- or ventilator-acquired pneumonia. It works by inactivating certain β-lactamases (Ambler class A, including Klebsiella pneumoniae carbapenemases; Ambler class C; and some Ambler class D β-lactamases) through a unique covalent and reversible mechanism. This action protects ceftazidime from degradation by these enzymes, restoring its activity against resistant Gram-negative bacteria. Avibactam does not possess antibacterial activity on its own but extends the spectrum of ceftazidime when used together[1][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avibactam.